[HTML][HTML] PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with replapsed or …
OA O'Connor, B Pro, L Pinter-Brown, L Popplewell… - Blood, 2008 - Elsevier
Background: Pralatrexate (PDX) is a novel targeted antifolate that is designed to accumulate
preferentially in cancer cells. Pralatrexate selectively enters cells expressing RFC-1, a …
preferentially in cancer cells. Pralatrexate selectively enters cells expressing RFC-1, a …
PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory …
OA O'Connor, B Pro, L Pinter-Brown, L Popplewell… - 2008 - ashpublications.org
Background: Pralatrexate (PDX) is a novel targeted antifolate that is designed to accumulate
preferentially in cancer cells. Pralatrexate selectively enters cells expressing RFC-1, a …
preferentially in cancer cells. Pralatrexate selectively enters cells expressing RFC-1, a …
PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory …
OA O'Connor, B Pro, L Pinter-Brown, L Popplewell… - Blood, 2008 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Background: Pralatrexate (PDX) is a novel
targeted antifolate that is designed to accumulate preferentially in cancer cells. Pralatrexate …
targeted antifolate that is designed to accumulate preferentially in cancer cells. Pralatrexate …